SAMHSA Just Made It Cheaper to Die Than to Know What You're Dying From

The Kentucky Harm Reduction Coalition ran its numbers for the first quarter of fiscal year 2026 before the email arrived. Forty-eight thousand, four hundred and sixty-five fentanyl test strips distributed in Q1 alone — more than four hundred strips a day, every day, handed to people who were about to inject something they couldn’t see, couldn’t smell, couldn’t taste, couldn’t identify. Fentanyl is invisible in that way. So is the decision about whether to put it in the supply. So is the amount. So is the question of whether it will kill you.

Then the email came. The director opened it on a Thursday in late April and learned that their federal grant — through SAMHSA’s programs of regional and national significance — was done. Not ending at year’s close, not subject to renegotiation. Done. The organization had three weeks of payroll.

Not because the program didn’t work. Because the federal government had decided that the program shouldn’t exist.

SAMHSA’s April 2026 ban on federal funding for fentanyl test strips, xylazine test strips, medetomidine test strips, and sterile syringes makes it federally illegal to use grant money on the cheapest, most evidence-based intervention between a person and an overdose death. This is not a policy disagreement. It is a decision about who gets to stay alive.

What a Test Strip Actually Does

Before we go further, let me say it plainly — the way you would say it to someone who has never seen one, not someone who needs to be convinced of a political position:

A fentanyl test strip costs between 89 cents and two dollars. You add a small amount of water. You dip the strip in a residue of the drug you are about to use — the rinse water from the container, the cooker, the bag. You wait ninety seconds. One line means fentanyl is present. Two lines means the test found none.

That’s the whole thing. That’s what the federal government banned funding for.

What does knowing change? Research published in Drug and Alcohol Dependence in 2019 followed people who inject drugs at syringe service programs in the Southeastern United States and found that those who received fentanyl test strips were significantly more likely to change their use behavior when the test returned positive — using less, using more slowly, using with someone present, not using alone. You cannot make that decision without the information. The strip provides the information.

A 2021 MMWR report on test strip distribution in Louisville, Kentucky found that 70% of participants who received a positive result on a fentanyl test strip reported changing at least one aspect of their use pattern in response. They used slower. They had naloxone closer to hand. They called someone to tell them where they were. They did not use alone.

These are the decisions that are available to you only if you have the information. SAMHSA has now defunded the information.

If you have ever dipped a strip before you used, you already know what the 89 cents buys. You know what it felt like to wait ninety seconds and what the answer changed about what you did next. What this policy takes from you is not just the strip. It is the decision.

The Scope of What’s Gone

The April 24 ban wasn’t targeted at one program. It covered every grant-funded program that purchases fentanyl test strips, xylazine test strips, medetomidine test strips, or sterile syringes or pipes for distribution. According to the Drug Policy Alliance, the federal cuts affecting harm reduction now total at least $345 million, with an additional $588 million cut from related prevention research. These are not marginal programs. They are the infrastructure of the community-based overdose response that has, by the CDC’s own numbers, helped drive the first sustained decline in overdose deaths the country has seen in more than a decade.

The CDC’s provisional data for the 12 months ending January 2026 shows 69,147 predicted drug overdose deaths — down 13.2% from the prior year. That decline did not happen because people stopped using drugs. It happened because naloxone got distributed, because test strips gave people information, because fentanyl awareness reached communities that had no other way to get it. The infrastructure being defunded is the infrastructure that drove that number down.

The CDC’s provisional data for the 12 months ending January 2026 shows 69,147 predicted drug overdose deaths — down 13.2% from the prior year.

The Kentucky Harm Reduction Coalition is one of the organizations the ban ends. There are dozens of others. Their combined capacity — measured in strips distributed per quarter, in needle exchanges per month, in naloxone kits delivered per year — is being wound down. Not replaced. Wound down.

We Have Seen This Calculation Before

In 1988, Congress banned federal funding for syringe and needle exchanges. The ban was not based on evidence — the evidence, which was available by 1988 and overwhelming by the mid-1990s, showed that needle exchanges reduced HIV transmission without increasing drug use. The ban was based on a calculation about what message the government wanted to send. Funding needle exchanges, congressional critics argued, sent the wrong message. It communicated that people who inject drugs deserve to stay alive while they are using.

The ban held, with brief and partial interruptions, for nearly three decades. During that time, Australia, the Netherlands, the United Kingdom, and most of Western Europe funded exchanges. Their HIV rates among people who inject drugs declined. The United States kept the ban and watched those rates stay elevated. The ban was permanently lifted — finally, in 2016, through the Consolidated Appropriations Act — after an estimated fifteen thousand Americans had acquired HIV through injection drug use who would not have if syringe exchange funding had been available.

Fifteen thousand people. A generation of public health policy. The wrong message.

We are watching the same calculation being made again, this time about fentanyl test strips. The strips are cheap. The evidence that they work is clear. The government has decided — explicitly, through an identifiable policy decision signed on April 24 — that the wrong message is: you deserve to know what you are about to put in your body.

What Happens to Programs Now

The organizations that received SAMHSA grants for test strip distribution have three options: find philanthropic replacement funding (the foundation space has been deluged since April and cannot absorb the full capacity loss), charge for strips (which immediately prices out the people most at risk — the same people the program was built for), or close the program.

Most will try the first option. A smaller number of well-funded urban programs will find bridge funding. The programs in rural Kentucky, in West Virginia, in Arizona’s reservation communities — where grant funding was not a supplement to an already-funded program but the entire program — will close. The people those programs served will not disappear. They will continue to use drugs. They will continue to encounter a drug supply laced with fentanyl, xylazine, and now medetomidine. They will do so without the information.

SAMHSA, meanwhile, announced $40 million in new funding on June 11 — for addiction prevention, child trauma, suicide prevention, and mental illness. The agency is not being defunded entirely. It is being redirected toward categories that communicate a different message about who deserves the investment.

Prevention for children. Treatment for people who have achieved the approved version of help. Not strips for people who are using right now and might die in the next hour.

The One Thing That Remains

Naloxone — the overdose reversal medication — remains federally funded, distributed through emergency management channels, and available for purchase without a prescription in most states. If you are reading this and you or someone you know uses opioids in any form: this is still yours. Find naloxone at a local pharmacy, a community health center, or through a harm reduction organization that has not yet closed. The program at GetNaloxone.org maintains a state-by-state resource directory that is still operational.

Naloxone works after an overdose has already started. Fentanyl test strips work before one does.

The federal government has decided you can have the first and not the second. Whether that calculation is acceptable — whether we count the dead it produces the way we eventually counted the dead from the syringe exchange ban — is the question the policy has now forced.

The federal government has decided you can have the first and not the second.

---

For help finding harm reduction services still operating in your area: rizerecovery.com/find-help. Report a harm reduction program closure or funding gap to the Drug Policy Alliance’s crisis tracker. Naloxone access: GetNaloxone.org.